The Brazil injectable drugs market comprises medicines which are administered into a patient's body with the help of injection. These include monoclonal antibodies, vaccines, insulins, cytokines, peptide hormones, blood factors, and immunoglobulins. Injectables provide benefits such as precise dosing, fast action, and avoidance of the gastrointestinal tract and hepatic first-pass metabolism. They are widely used to treat medical conditions including cancer, diabetes, infectious diseases, and cardiovascular disorders. With the rising prevalence of chronic diseases and increasing healthcare expenditure in Brazil, demand for injectable drugs is growing rapidly.
The global Brazil Injectable Drugs Market is estimated to be valued at US$ 9353.45 Mn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The key trend augmenting the growth of Brazil injectable drugs market is rising adoption of self-injectable drugs. Self-injectable drugs help patients administer medicines independently and offer convenience over traditional methods of drug delivery. This has led pharmaceutical companies to focus on developing self-administrable drug formulations for chronic diseases like diabetes and autoimmune disorders. Furthermore, advancement in drug delivery technologies is enabling development of more effective and user-friendly self-injection systems such as prefilled syringes and wearable injectors. Rising popularity of home healthcare is also propelling the use of self-administered injectable drugs for cost-effective long-term treatment outside hospitals and clinics. Due to these factors, self-injectable drugs segment is growing at a higher rate in the Brazil injectable drugs market compared to conventional injectables administered by healthcare professionals.
Segment Analysis
The Brazil injectable drugs market for hospitals & ambulatory settings is dominated by generic injectable drugs sub-segment. Generic injectable drugs account for over 60% share owing to their cost-effectiveness and ability to treat chronic conditions like diabetes, cancer, and cardiovascular diseases which affects a large population base in Brazil. Biosimilars sub-segment is expected to witness highest growth during the forecast period due to increasing research and development activities for developing cost-effective biosimilars by pharmaceutical companies.
Key Takeaways
The global Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings Growth is expected to witness high growth. The global Brazil Injectable Drugs Market is estimated to be valued at US$ 9353.45 Mn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030.
Regional analysis
The South region accounts for maximum share in the Brazil injectable drugs market led by states like Sao Paulo and Rio de Janeiro due to concentration of key hospitals and research centers. The Northeast region is forecasted to grow at fastest pace during the forecast period due increasing healthcare infrastructure development under public-private partnerships.
Key players
Key players operating in the Brazil injectable drugs market for hospitals & ambulatory settings are Danaher Corporation, Agilent Technologies, Thermo Fisher Scientific, Merck KGaA, Stratedigm Inc., Bio-Rad Laboratories, Nikon Corporation. Danaher Corporation leads the market owing to its broad product portfolio for injectable drugs, biologics and biosimilars production.
For more insights, read- https://www.ukwebwire.com/brazil-injectable-drugs-market-for-hospitals-ambulatory-settings-trends-size-and-share-analysis/
Comments
0 comment